AstraZeneca PLC (AZN)vsLantheus Holdings Inc (LNTH)
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
LNTH
Lantheus Holdings Inc
$100.98
-1.79%
HEALTHCARE · Cap: $6.80B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 3809% more annual revenue ($60.44B vs $1.55B). LNTH leads profitability with a 18.0% profit margin vs 17.2%. LNTH appears more attractively valued with a PEG of 0.61. LNTH earns a higher WallStSmart Score of 67/100 (B-).
AZN
Buy64
out of 100
Grade: C+
LNTH
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
-2.1%
Fair Value
$65.91
Current Price
$100.98
$35.07 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Earnings expanding 76.5% YoY
Conservative balance sheet, low leverage
Every $100 of equity generates 23 in profit
Growing faster than its price suggests
Strong operational efficiency at 21.6%
Areas to Watch
Moderate valuation
Distress zone — elevated risk
1.2% revenue growth
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : LNTH
The strongest argument for LNTH centers on EPS Growth, Debt/Equity, Return on Equity. Profitability is solid with margins at 18.0% and operating margin at 21.6%. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : LNTH
The primary concerns for LNTH are Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while LNTH is a value play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.21 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
LNTH scores higher overall (67/100 vs 64/100), backed by strong 18.0% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Lantheus Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Lantheus Holdings, Inc. develops, manufactures and markets diagnostic and therapeutic agents and products that assist physicians in the diagnosis and treatment of heart, cancer and other diseases worldwide. The company is headquartered in North Billerica, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?